PTACH
CAS No. : 848354-66-5
(Synonyms: NCH-51)
| Size | Price | Stock |
|---|---|---|
| 1mg | $53 | In-stock |
| 5mg | $120 | In-stock |
| 10mg | $181 | In-stock |
| 25mg | $362 | In-stock |
| 50mg | $544 | In-stock |
| 100mg | $816 | In-stock |
| 200 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-12954 |
| M.Wt: | 390.56 |
| Formula: | C20H26N2O2S2 |
| Purity: | >98 % |
| Solubility: | DMSO : 50 mg/mL (ultrasonic) |
PTACH (NCH-51) is a potent HDAC inhibitor with IC50s of 48 nM, 32 nM, and 41 nM for HDAC1, HDAC4, and HDAC6, respectively. PTACH exerts potent growth inhibition against various cancer cells (EC50s of 1.1-9.1 µM) [1][2].
In Vitro: PTACH (compound 51) treatment elevates the levels of acetylated histone H4 and p21WAF1/CIP1 in a dose-dependent manner[1].
In cancer cell growth inhibition assay, PTACH (compound 51) shows strong activity. PTACH inhibits various cancer cells with EC50 values of 2.3 μM, 9.1 μM, 3.0 μM, 2.6 μM, 1.1 μM, 4.5 μM, 2.4 μM, 5.0 μM, and 4.5 μM for MDA-MB-231, SNB-78, HCT116, NCI-H226, LOX-IMVI, SK-OV-3, RXF-631L, St-4, and DU-145 cells, respectively[1].
PTACH (NCH-51) augments the HIV-1 production in latently infected OM10.1 cells and such reactivation is associated with a loss of HDAC1 occupancy and subsequent hyperacetylation of histones in nuc-1 at the HIV-1 promoter[2].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- PTACH
- Cat. No.:
- HY-12954
- Quantity:
Your information is safe with us.